Fact Check: The Patent Eligibility Restoration Act Would Promote Medical Innovation
Claim: During a January 23 Senate Judiciary Subcommittee on Intellectual Property hearing, Richard Blaylock — on behalf of Invitae Corporation — claimed that “PERA as introduced would stifle innovation and harm patient care in the fields of diagnostic genetic testing and precision medicine.” Correction: The Patent Eligibility Restoration Act (PERA) is an essential reform to